The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Weedylan, I agree with your interpretation, and the December roll out for evaluation makes sense of a note sent to me by an MP during November…
“ the government is planning to diversify the supply of LFTs and these plans will be expanded over the coming months.”
I’ll make enquiries with regard to Avacta’s participation at our local pharmacy… but it’s a small outlet, maybe another BB member has a better contact?
I’m pretty disappointed by responses I get from our local MP, who seems to just parrot the party line. So I was thrilled to hear Harvey Neale MP pose his question in Parliament. The response from Shadow health Secretary Wes Streeting however, was not thrilling, rather it was gut wrenchingly tepid and completely missed the point, an opportunity missed.
I’ve written to Wes Streeting to educate him regarding Chinese LFT’s and the ongoing UK diagnostics saga, particularly Avacta’s, providing an example response that he could have, or should have made. I look forward to his reply.
New Director of Operations
https://twitter.com/hummerston_p/status/1446851743829086210
Snipped from a response from within the government to my ongoing remonstration with regard to the treatment of UK companies like AVCT during the pandemic, especially compared to the free reign given to companies providing ineffectual Chinese derived LFT’s.
The second para at least confirms that plans for shaking up the provision of LFT’s in the UK is in the government’s plan?
…
Whilst I understand your concerns about sourcing these devices from abroad the sheer volume of tests required necessitated swift action by the government, and sourcing all of our tests from within the UK simply would not have been possible at such short notice.
You may be interested to learn however that the government is planning to diversify the supply of LFTs and these plans will be expanded over the coming months. I will be following developments closely.
Very good ST! I can empathise with that. With AVCT it’s probably best to go away, come back in May, see the SP in the £’s and be totally oblivious of the heart wrenching roller coaster, false dawns, hopes and conspiracies and gates between now and then. Oh the bliss :)
Look back in the following May and it’ll likely be even better :)
I mentioned earlier that Medusa haven’t broadcast a single tweet since July.
In fact the last Medusa tweet was 14-July, just a week or so before their MD resigned, according to Companies House.
It’s odd that the MD still has a profile on the Medusa website, even though he resigned four months ago. Although, fair to say that the site hasn’t been updated for a nearly a year.
All very curious.
Timster, eerily quiet is one thing, but Medusa haven’t broadcast a single tweet since July! Their website is quite basic and hasn’t been updated for a nearly a year, and Meduflow is revealed to the world via a random tweet from a passer by? …. all completely at odds with the massive expectation we have of the company?
Can anyone suggest anything other the fallback NDA as a reason for the odd behaviour?
ps: Having said that, @downunderfutbol’s tweet revealing the existence of MeduFlow still came as a welcome and incredibly exciting surprise! Like many on this board, I’m happily overweight in AVCT, and deep underwater!
Like many on this board, I’m happily overweight in AVCT, but deep underwater! So @downunderfutbol’s tweet revealing the existence of MeduFlow came as a welcome and incredibly exciting surprise!
But can anyone here shed any light on why Medusa aren’t tweeting about it themselves. It’s bothered me that Medusa hasn’t broadcasted a single tweet since July, or even updated their website for a nearly a year… and in my mind this is completely at odds with the massive expectation we have of the company?
Article published 6-December:
https://www.modernhealthcare.com/supply-chain/testing-asymptomatic-patients-becomes-more-prevalent-and-useful
It states:
“Avacta is developing a saliva-based rapid SARS-CoV-2 antigen test with Cytiva.”
The following article was published in the quite recent past on 6-DECEMBER, supporting the idea that the Cytiva/Avacta relationship is alive and well.
https://www.modernhealthcare.com/supply-chain/testing-asymptomatic-patients-becomes-more-prevalent-and-useful
Quote of interest:
“Avacta is developing a saliva-based rapid SARS-CoV-2 antigen test with Cytiva.”
In case anyone missed it, Mologics LFT manufacturing (GAD) capacity is planned to be 1 Million per day (250m p/annum) by May this year.
From yesterday’s FT article:
Global Access Diagnostics, which currently has 70 employees but is planning to hire another 210 by April, is a high volume manufacturing enterprise in Bedfordshire, which spun out from the diagnostics firm Mologic last year. It has received close to £1m in funding from the UK government and around £10m in equipment, according to Mark Radford, the company’s executive director.
The company aims to expand its annual production of lateral flow tests from 40m to 250m by early May.